Tuesday, October 5, 2010

CryoLife Appoint D.P. Lang - VP Market Development

ATLANTA, Oct 04, 2010 /PRNewswire via COMTEX/ -- CryoLife, Inc. (CRY 6.17, +0.17, +2.83%), an implantable biological medical device and cardiovascular tissue processing company, announced today that it has appointed David P. Lang as vice president of market development for CryoLife International Inc. In this newly created position, Mr. Lang will have responsibility for coordinating and developing the international marketing and distribution strategies for PerClot, a novel hemostatic agent that the Company recently licensed from Starch Medical Inc. Mr. Lang will report to Gerald B. Seery, senior vice president sales and marketing and president, CryoLife International, Inc.
A graduate of Harvard University with a degree in economics, Mr. Lang began his career at Medtronic in 1970 and has held sales and marketing positions of increasing responsibility throughout his medical device marketing and management career. From 2008 to 2010, Mr. Lang served as the president and was a consultant to Starch Medical Inc. He served as vice president of international sales and marketing for Medafor, Inc. from 2001 to 2008, where he established their European, Latin American and Asian distribution networks.

Kraig Biocraft Laboratories Announces Application for Trademark of Spider Silk ...

LANSING, MI, Oct 05, 2010 (MARKETWIRE via COMTEX) -- Kraig Biocraft Laboratories, Inc.(KBLB 0.15, +0.03, +22.92%) announced today that that it has filed intent to use applications with the US Patent and Trademark office seeking registration of numerous marks for the purpose of branding recombinant silk fibers.
"The Company views branding of our recombinant silk to be just as important as it is with any other product line. It is anticipated that the proposed marks will enhance product marketability and distinguish our advanced technology from other fibers in the marketplace," said Kim Thompson, the Company's CEO and founder. "This is just the beginning of the Company's efforts to further distinguish itself in the market place as we move toward the commercialization of our technology."
The intent to use applications included seven separate proposed marks including Spiderpillar(TM) and Monster Silk(TM).
The Company recently announced the successful development of recombinant spider silk based fibers using genetic engineering. 
The Company will also hold a shareholder press conference on Friday, October 8, 2010 at 4:30 p.m. EDT and will issue a reminder press release the morning of the conference call, which will include the phone number and access code instructions.

Nordson Corporation Enters Agreement to Acquire Micromedics, Inc.

WESTLAKE, Ohio, Oct 05, 2010 (BUSINESS WIRE) -- Nordson Corporation (NDSN 75.00, +3.31, +4.62%) today announced it has entered into a definitive agreement to acquire St. Paul, Minnesota-based Micromedics Inc., a leader in applying and dispensing biomaterials for controlling bleeding, healing wounds and other related medical procedures. Terms of the deal, which is expected to close within approximately 30 days, were not disclosed.
"The Micromedics acquisition fits Nordson's growth strategy of purchasing high performing market leaders with differentiated technology and a significant recurring revenue stream," said Nordson President and CEO Michael F. Hilton. "Micromedics extends Nordson's expertise in precision dispensing technology and helps grow our existing position in the rapidly expanding medical device industry. The market for biomaterial applicators in particular is expected to continue growing due to an expanding range of applications, the continuing introduction of new types of biomaterials, and more widespread reimbursement for procedures using these products."
"The functionality, ease of use and recognized performance advantages of Micromedics products provides significant differentiation in the market and drives customer loyalty," said Micromedics President Curt Miller. "Nordson's global presence, technology leadership and ability to invest should enable Micromedics to build on these strengths, expand its position as a leading provider in the global medical device market, and provide its employees with multiple opportunities for growth."
Micromedics bioapplicator products are marketed under the name FibriJet and include single and dual syringe applicators modified with interchangeable tips for the particular needs of specific surgical procedures. The products enable the controlled dispense of a single material or simultaneous dispense of two materials to a localized treatment site with simple, one-handed operation. The products are sold to a wide variety of end customers, including distributors, surgeons, OEMs, hospitals and outpatient clinics.
The acquired business will be integrated into Nordson's Advanced Technology Systems segment. Additional Micromedics product lines related to ear, nose and throat applications and surgical instrument protection are not being acquired by Nordson and will be spun out prior to close as a new company called Summit Medical Inc.